Top of the page.
Skip the menu to main contents.
Move to main menu.
Skip to main contents.


Main menu starts here.
Skip the main menu to current location in your website.

Current location in your website.
Skip to main contents.


Synergy within the Fujifilm Group

 

By applying Fujifilm Group's total solutions, we are contributing to the progress of nuclear medicine and further expanding our areas of activity.

In the recent nuclear medicine field, what is most demanded is the total solution integrating equipment, software, materials and drugs. As the link between diagnosis and treatment is getting stronger, FUJIFILM RI Pharma, through supply of nuclear pharmaceuticals, has expanded its diagnostic business to include treatment. We are also engaged in new efforts in collaboration with Fujifilm.

For example, we are working on an image diagnostic system that incorporates our unique nuclear medicine software, for use with Fujifilm's imaging and information management system SYNAPSE, which tops the domestic market share. Also, with Fujifilm's unique advanced image processing technology and nanotechnology, a synthesis chemistry, we are developing new radioactive pharmaceuticals that contribute to diagnosis and treatment by nuclear medicine.

While enhancing the reliability and efficiency of nuclear medicine imaging, FUJIFILM RI Pharma, as a member of Fujifilm Group whose activities in the medical field include prevention, diagnosis and treatment, is creating total solutions for building an integrated business system covering R&D, manufacture, distribution and sales of new drugs. Determined to be a leading nuclear medicine company, we will keep on creating new values.

[Image]Group Synergy in Fujifilm Group’s Medical Systems and Life Science Businesses

Related Information

Introduction about Group companies with FUJIFILM Holdings Corporation at the core.


Footer starts here.

Pages ends here.
Move to top of the page.